Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

This study has been completed.
Otsuka Pharmaceutical Development & Commercialization, Inc.
Information provided by (Responsible Party):
GW Pharmaceuticals Ltd. Identifier:
First received: December 16, 2010
Last updated: July 4, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 24, 2016